American Healthcare REIT's Stretched Valuation Meets Growth Normalization

What happened

American Healthcare REIT has experienced a dramatic 4.5x share price surge since its February 2024 IPO, driven by aggressive equity issuance and a string of accretive acquisitions that fueled investor enthusiasm. The company's portfolio, however, remains heavily weighted toward skilled nursing and senior housing operating assets where asset quality and EBITDAR coverage modestly lag top peers, exposing it to labor and reimbursement risks. At a current valuation of 25.5x 2027E AFFO, the market is pricing in sustained double-digit same-store NOI growth and over 10% NFFO per share expansion, but evidence points to growth normalizing toward high-single-digits as occupancy gains moderate. The DeepValue master report had already flagged the stock as a potential sell above $52, with a bear case implying $38 and a base case of $50, noting that heavy reliance on ATM and forward equity issuance adds dilution risk. The newly published Seeking Alpha article reinforces these concerns, explicitly urging investors to 'pump the brakes' because the stock's appreciation has outstripped its underlying fundamentals and leaves limited margin of safety.

Implication

The article's caution aligns with the DeepValue report's 'potential sell' rating and trimmed upside expectations, suggesting that the stock may have already priced in the best-case scenario for continued growth. With the stock trading near $47 and the master report's trim threshold at $52, the approaching ceiling indicates limited room for further appreciation without a material improvement in fundamentals. The base case of high-single-digit same-store NOI growth and mid-single-digit NFFO per share growth implies a total return of only high-single-digits over 12–18 months, which is unattractive relative to the risk of multiple compression. Should 2026 guidance show a step-down in growth or if acquisition spreads narrow, the bear case of $38 becomes plausible, representing a meaningful downside from current levels. Therefore, investors should consider reducing exposure or at least avoid adding new capital until either the valuation compresses toward the $40 entry point or management delivers clear evidence of sustained above-sector growth with disciplined capital deployment.

Thesis delta

The latest article does not change the fundamental thesis but reinforces existing concerns about valuation and growth deceleration. The shift, if any, is increased confidence in the bear case due to mounting evidence that the market is overly optimistic. The thesis remains that AHR is a potential sell or trim, with the risk of dilution and normalization of NOI growth becoming more pronounced as the share price has surged beyond intrinsic value.